LL-37 research in Canada investigates the antimicrobial, immunomodulatory, and wound-healing properties of this human cathelicidin. LL-37 is the only human cathelicidin and is derived from the C-terminal region of the hCAP18 protein stored in neutrophil granules. Canadian researchers study LL-37 as a host defence peptide with roles in both innate immunity and wound healing signalling.
Antimicrobial Properties Research
LL-37 is an amphipathic alpha-helical peptide that disrupts bacterial membranes through electrostatic interactions. Canadian microbiology researchers study LL-37’s activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses in cell-free and cell-culture assays. Its broad-spectrum activity makes it a valuable tool for antimicrobial peptide (AMP) research.
Immune Modulation Research
Beyond antimicrobial activity, LL-37 is studied for its immunomodulatory properties. It activates formyl peptide receptor 2 (FPR2), promotes dendritic cell maturation, and modulates cytokine production. Canadian immunology researchers use LL-37 to investigate innate immune signalling networks in macrophage and dendritic cell models.
Wound Healing Research
LL-37 is studied for its role in promoting keratinocyte migration, angiogenesis, and re-epithelialization in wound model research. Canadian dermatology researchers use LL-37 to investigate host defence peptide contributions to wound healing biology.
Sourcing LL-37 in Canada
Research-grade LL-37 (Cathelicidin) is available in Canada from EhBuddy Peptides. Lab-tested for purity. For laboratory research use only.
LL-37 is a uniquely versatile research peptide in Canada, bridging antimicrobial science, immunology, and wound biology research.
